enGene (NASDAQ:ENGN) Now Covered by Wells Fargo & Company

Wells Fargo & Company began coverage on shares of enGene (NASDAQ:ENGN) in a report issued on Monday morning, MarketBeat.com reports. The brokerage issued an overweight rating and a $30.00 price objective on the stock.

Several other brokerages have also recently commented on ENGN. Morgan Stanley started coverage on shares of enGene in a research note on Friday, March 8th. They issued an overweight rating and a $40.00 price target on the stock. UBS Group initiated coverage on enGene in a research note on Thursday, March 28th. They issued a buy rating and a $37.00 price objective for the company. Guggenheim began coverage on enGene in a report on Monday, April 15th. They issued a buy rating and a $34.00 target price for the company. Leerink Partnrs reaffirmed an outperform rating on shares of enGene in a research note on Tuesday, February 20th. Finally, SVB Leerink began coverage on shares of enGene in a report on Tuesday, February 20th. They issued an outperform rating and a $31.00 target price for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of Buy and a consensus price target of $34.40.

enGene Price Performance

NASDAQ:ENGN opened at $14.72 on Monday. enGene has a 12-month low of $6.69 and a 12-month high of $43.00. The stock’s 50-day simple moving average is $16.21.

Insider Transactions at enGene

In related news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the company’s stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of $15.00, for a total value of $717,810.00. Following the completion of the sale, the insider now directly owns 3,036,153 shares of the company’s stock, valued at $45,542,295. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ENGN. Fcpm Iii Services B.V. bought a new position in enGene in the fourth quarter worth about $80,097,000. BVF Inc. IL acquired a new stake in enGene during the 4th quarter worth about $20,777,000. Omega Fund Management LLC acquired a new stake in shares of enGene during the 4th quarter worth approximately $10,441,000. Finally, Vivo Capital LLC purchased a new position in shares of enGene during the 4th quarter valued at approximately $6,264,000. 64.16% of the stock is owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.